Zura Bio Limited Class A Ordinary Shares (ZURA : NASDAQ)
Common Stock
Follow ZURA
ZURA
Zura Bio Limited Class A Ordinary Shares
WealthAwesomePerformance
1 Day
+13.31%
1 Week
-64.79%
1 Month
-64.88%
YTD
-61.19%
The Saturday TSX Wrap · free, every saturday morning. The week on the TSX, in five minutes.
Key Statistics
Market Cap
$135.34M
52W High
$7.44
52W Low
$0.93
P/E Ratio
-
50 Day MA
$4.36
200 Day MA
$5.17
Beta
0.02
Dividend Yield
-
Performance history
ZURA returns since 2026
Zura Bio Limited Class A Ordinary Shares has traded since Jun 2026 in our data. Its deepest fall was −80.4% (Aug 2026 to Nov 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2026*−61.2%
* Partial year (first year of data, or year to date).
$10,000 invested in ZURA
- 2026 (start of our data)$3,881
- All-time high in our data
- $6 on Aug 25, 2026 · now −77.8%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past ZURA? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/10/2026 | $1.17 | $1.53 | $1.16 | $1.41 | $1.41 | 16,934,637 |
| 11/9/2026 | $1.27 | $1.27 | $0.93 | $1.24 | $1.24 | 63,738,064 |
| 11/6/2026 | $3.80 | $4.25 | $3.76 | $4.09 | $4.09 | 3,002,600 |
| 11/5/2026 | $4.00 | $4.01 | $3.70 | $3.72 | $3.72 | 2,653,802 |
| 11/4/2026 | $4.12 | $4.20 | $3.83 | $4.02 | $4.02 | 1,945,840 |
| 11/3/2026 | $3.99 | $4.13 | $3.90 | $3.99 | $3.99 | 1,929,717 |
| 11/2/2026 | $4.04 | $4.14 | $3.87 | $3.94 | $3.94 | 3,719,456 |
| 10/30/2026 | $3.81 | $4.06 | $3.65 | $4.04 | $4.04 | 4,074,200 |
| 10/29/2026 | $4.35 | $4.49 | $3.80 | $3.85 | $3.85 | 3,326,011 |
| 10/28/2026 | $4.23 | $4.60 | $4.11 | $4.35 | $4.35 | 4,376,083 |
Analyst Price Targets
Based on 7 analysts covering ZURA · as of Nov 11, 2026
Wall Street analysts forecast ZURA stock price to rise 1081.5% over the next 12 months.
Consensus
Strong Buy4.86 / 5.00
Avg. Target
US$16.60
+1081.5% Upside
Previously US$19.00 on Oct 26, 2026
Current Price
US$1.41
Last close
Analyst Breakdown (7 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ZURA's historical volatility
30-Day Vol
364.3%
Annualized
90-Day Vol
215.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$1.18
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$1.32 | US$0.38 – US$4.65 |
| 60 trading days | US$1.25 | US$0.21 – US$7.38 |
| 90 trading days | US$1.18 | US$0.13 – US$10.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-101.94M
- Profit Margin
- 0.00%
- ROE (TTM)
- -63.17%
- EPS (Diluted)
- -1.11
- Book Value
- 1.84
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Saturday TSX Wrap
The week on the TSX, in five minutes
- The biggest gainers and losers, and why they moved
- Sector and momentum moves at a glance
- The Canadian market stories you missed
Explore More
Common Questions About ZURA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SMX | SMX (Security Matters) Public Limited Company Class A Ordinary Shares | $19.25 | +105.88% |
| PEPG | PepGen Ltd | $4.61 | +92.89% |
| TTEC | TTEC Holdings Inc | $2.40 | +72.04% |
| NNOX | Nano X Imaging Ltd | $0.37 | +59.80% |
| TANH | Tantech Holdings Ltd | $30.56 | +58.01% |
| AACG | ATA Creativity Global | $0.89 | +52.14% |
| ESLA | Estrella Immunopharma Inc. | $0.75 | +45.40% |
| MNDO | MIND CTI Ltd | $1.26 | +44.83% |
Free with a Wealth Awesome account
Keep analysing ZURA, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.